Levels of Interleukin-6 and D-Dimer in Paediatric Patients with Renal Injury at the Federal University Teaching Hospital Owerri
Main Article Content
Abstract
Background: Interleukin-6 (IL-6) and D-dimer have been identified as potential biomarkers of the pathological processes that lead to the progression of chronic kidney disease (CKD) in paediatric patients, including systemic inflammation and coagulation abnormalities. This study aimed to evaluate IL-6 and D-dimer levels in paediatric CKD patients and assess their associations with disease severity and clinical outcomes.
Method: A cross-sectional study was carried out at the Federal Teaching Hospital, Owerri, involving 120 paediatric patients (aged 1–18 years) with CKD stages 2–5 or undergoing renal replacement therapy (RRT). IL-6 and D-dimer levels were measured and correlated with mortality, disease progression, the need for RRT, and estimated glomerular filtration rate (eGFR). Statistical analyses included ANOVA and correlation tests.
Result: The severity of CKD was positively correlated with IL-6 and D-dimer levels (p < 0.001). Disease progression (p = 0.002), RRT requirement (p < 0.001), and mortality (p < 0.001) were all substantially correlated with higher biomarker levels. There was a negative correlation between eGFR, D-dimer, and IL-6 (r = -0.45, p < 0.01). In children, poor clinical outcomes and the advancement of chronic kidney disease are closely linked to elevated levels of IL-6 and D-dimer.
Conclusion: Regular tracking of these biomarkers could improve risk assessment and direct early intervention. To fully understand their therapeutic implications and mechanistic role, more research is required.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Journal is owned, published and copyrighted by the Nigerian Medical Association, River state Branch. The copyright of papers published are vested in the journal and the publisher. In line with our open access policy and the Creative Commons Attribution License policy authors are allowed to share their work with an acknowledgement of the work's authorship and initial publication in this journal.
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author.
The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations. While the advice and information in this journal are believed to be true and accurate on the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.
TNHJ also supports open access archiving of articles published in the journal after three months of publication. Authors are permitted and encouraged to post their work online (e.g, in institutional repositories or on their website) within the stated period, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). All requests for permission for open access archiving outside this period should be sent to the editor via email to editor@tnhjph.com.
How to Cite
References
1. Warady BA, Chadha V. Chronic kidney disease in children: the global perspective. Pediatr Nephrol. 2007 Dec;22(12):1999-2009. doi: 10.1007/s00467-006-0410-1. Available from: https://link.springer.com/article/10.1007/s00467-006-0410-1
2. Sinha R, Agarwal S, Sethi SK. Inflammation and oxidative stress in children with chronic kidney disease: a concise update. Indian J Nephrol. 2020 Jan-Feb;30(1):4-9. doi: 10.4103/ijn.IJN_267_18. Available from: https://pubmed.ncbi.nlm.nih.gov/31906008/
3. Kaysen GA, Greene T, Daugirdas JT. Inflammation and nutritional status in dialysis patients. Kidney Int Suppl. 2002 May;(80):S89-S96. doi: 10.1046/j.1523-1755.61.s80.14.x. Available from: https://www.kidney-international.org/article/S0085-2538(15)49265-6/fulltext
4. Tocci G, Sciarretta S, Volpe M. Interleukin-6 in hypertension and cardiovascular disease: a review of the latest scientific evidence. J Hypertens. 2008 Oct;26(10):2035-8. doi: 10.1097/HJH.0b013e32830d639b. Available from: https://journals.lww.com/jhypertension/Abstract/2008/26030/Interleukin_6_in_hypertension_and_cardiovascular.2.aspx
5. Kocyigit I, Yilmaz MI, Orscelik O, Unal A. Interleukin-6 levels as a predictor of mortality in hemodialysis patients. Am J Nephrol. 2010;31(3):280-8. doi: 10.1159/000276758. Available from: https://www.karger.com/Article/Abstract/276758
6. Goldstein SL, Leung JC, Silverstein DM. Pro- and anti-inflammatory cytokines in chronic pediatric dialysis patients: effect of vitamin E. Kidney Int. 2003 Aug;64(2):477-85. doi: 10.1046/j.1523-1755.2003.00083.x. Available from: https://www.kidney-international.org/article/S0085-2538(15)49285-1/fulltext
7. Coresh J, Selvin E, Stevens LA. Prevalence of chronic kidney disease in the United States. JAMA. 2007 Nov 7;298(17):2038-47. doi: 10.1001/jama.298.17.2038. Available from: https://jamanetwork.com/journals/jama/fullarticle/209246
8. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008 Aug 28;359(9):938-49. doi: 10.1056/NEJMra0801082. Available from: https://www.nejm.org/doi/full/10.1056/NEJMra0801082
9. Lippi G, Favaloro EJ. D-dimer testing in laboratory diagnostics: the case for a threshold change. Semin Thromb Hemost. 2020 Jan;46(1):15-9. doi: 10.1055/s-0039-1701025. Available from: https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0039-1701025
10. Filler G, Clark H, Edefonti A. Cardiovascular disease in children with chronic kidney disease: research advances and challenges. Clin J Am Soc Nephrol. 2014 Dec 5;9(12):2159-67. doi: 10.2215/CJN.03790414. Available from: https://cjasn.asnjournals.org/content/9/12/2159
11. Nitsch D, Grams M, Sang Y, Black C. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure in children with CKD. J Am Soc Nephrol. 2013 Aug;24(8):1354-61. doi: 10.1681/ASN.2012111092. Available from: https://jasn.asnjournals.org/content/24/8/1354
12. Shroff R, Long DA. Vascular calcification in children with CKD: lessons from animal models. Pediatr Nephrol. 2017 Sep;32(9):1625-34. doi: 10.1007/s00467-016-3424-5. Available from: https://link.springer.com/article/10.1007/s00467-016-3424-5
13. Matsushita K, Sang Y, Ballew SH. Subclinical and clinical cardiovascular disease burden among children with chronic kidney disease. Circulation. 2016 Jul 19;134(3):178-85. doi: 10.1161/CIRCULATIONAHA.116.021253. Available from: https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.116.021253
14. Schwartz GJ, et al. "New equations to estimate GFR in children with CKD." Journal of the American Society of Nephrology, 2009.
15. Barreto FC, Barreto DV, Liabeuf S, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int. 2010;77(6):550-556. doi:10.1038/ki.2009.503. Available from: https://www.kidneyinternational-online.org/article/S0085-2538%2815%2954300-7/fulltext
16. Karava V, Kondou A, Dotis J, et al. Exploring systemic inflammation in children with chronic kidney disease: correlates of interleukin 6. Pediatr Nephrol. 2024;39(8):1567-1576. doi:10.1007/s00467-023-06234-z. Available from: https://link.springer.com/article/10.1007/s00467-023-06234-z
17. Ridker PM, Devalaraja M, Baeres FM, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060-2069. doi:10.1016/S0140-6736(21)00520-1. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00520-1/fulltext:contentReference[oaicite:32]{index=32}